FDA Approves Tessie (Tasipimidine) for Canine Noise Aversion and Separation Anxiety
核心洞察
The U.S. Food and Drug Administration approved Tessie (搜索) (tasipimidine) oral solution on May 6, 2026, marking the first veterinary approval for this Orion proprietary molecule in the United States.
Tasipimidine acts in the central nervous system by blocking the startle reflex to counteract arousal, providing a novel mechanism for treating noise aversion and separation anxiety in dogs.
Zoetis will exclusively market and sell Tessie (搜索) in the United States starting mid-2027, expanding their behavioral product portfolio alongside existing treatments Sileo and Bonqat.
Orion Animal Health (搜索) has received U.S. Food and Drug Administration approval for Tessie (搜索) (tasipimidine) oral solution for dogs, marking a significant milestone in veterinary behavioral medicine. The FDA granted approval on May 6, 2026, for the treatment of noise aversion and separation anxiety in dogs.
Novel Mechanism of Action
Tasipimidine represents an Orion proprietary molecule and a new active substance for veterinary use in the United States. The drug acts in the central nervous system by blocking the startle reflex and thus counteracting arousal, offering a distinct therapeutic approach for behavioral disorders in canines.
"This approval adds to Orion Animal Health (搜索)'s portfolio of veterinary medicines developed to address clearly identified clinical needs," says Niclas Lindstedt, Executive Vice President of Orion Animal Health. "Our long-standing approach to innovation is centered on applying scientific expertise to create treatment options that support veterinary decision-making and animal welfare."
Commercial Partnership and Market Launch
Orion's long-standing strategic partner, Zoetis, has secured exclusive rights to market and sell Tessie (搜索) in the United States. The product is anticipated to be available in the U.S. by mid-2027 and will expand Zoetis' behavioral product portfolio, joining existing treatments Sileo and Bonqat.
Company Background
Orion Pharma Animal Health, part of Orion Corporation, focuses on improving the health and well-being of animals through science-based veterinary medicines and animal health solutions, with a strong emphasis on companion animals. The division develops, manufactures and markets a broad portfolio of proprietary and generic products, working closely with veterinary professionals.
Orion Pharma is a globally operating Nordic pharmaceutical company that has been building well-being for over a hundred years. The company develops, manufactures and markets human and veterinary pharmaceuticals as well as active pharmaceutical ingredients. In 2025, Orion's net sales amounted to EUR 1,890 million, with approximately 4,000 professionals worldwide dedicated to building well-being.
Zoetis, the world's leading animal health company, operates with a singular purpose to nurture the world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries.